Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + metronidazole + sitafloxacin eradication therapy for non-Helicobacter pylori Helicobacter infection
jRCTs031260484Recruiting
- Sponsor
- Yokohama City University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan, metronidazole and sitafloxacin in non-Helicobacter pylori Helicobacter infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate. Started Oct 2026; status: recruiting.
02
Drugs
vonoprazanmetronidazolesitafloxacin
03
Conditions
non-Helicobacter pylori Helicobacter infection
Beyond the preview
Go deeper on jRCTs031260484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260484.